Your browser doesn't support javascript.
loading
Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database.
Qasrawi, Ayman; Gomes, Victor; Chacko, Charles Andrew; Mansour, Akila; Kesler, Melissa; Arora, Ranjana; Wei, Sainan; Ramlal, Reshma; Munker, Reinhold.
Afiliación
  • Qasrawi A; Department of Medicine, University of Kentucky, Lexington, KY, USA.
  • Gomes V; Federal University of Ceara, Fortaleza, Brazil.
  • Chacko CA; Department of Medicine, University of Kentucky, Lexington, KY, USA.
  • Mansour A; Department of Pathology, University of Kentucky, Lexington, KY, USA.
  • Kesler M; Department of Pathology, University of Kentucky, Lexington, KY, USA.
  • Arora R; Department of Pathology, University of Kentucky, Lexington, KY, USA.
  • Wei S; Department of Pathology, University of Kentucky, Lexington, KY, USA.
  • Ramlal R; Department of Medicine, University of Kentucky, Lexington, KY, USA.
  • Munker R; Department of Medicine, University of Kentucky, Lexington, KY, USA. Electronic address: rmunker@uky.edu.
Leuk Res ; 89: 106301, 2020 02.
Article en En | MEDLINE | ID: mdl-31982153
Acute undifferentiated leukemia (AUL) is rare and defined by the absence of bona fide myeloid and lymphoid markers. Little is known about its incidence, survival and optimal management in the recent time period. Based on a case observed in our clinic, we queried the Surveillance, Epidemiology, and End Results database between 2000 and 2016. A total of 1,888 cases of AUL were diagnosed (1.34 per million person-years). The incidence of AUL has significantly decreased over time. Compared to other acute leukemias, patients with AUL have the highest median age (74 years); in contrast to acute myeloid leukemia (AML, 65) and acute lymphoblastic leukemia (ALL, 12). Excluding patients with preexisting malignancies, 1,444 patients with AUL were analyzed for survival. Only 35% of AUL patients had received chemotherapy. Comparatively, 94% of ALL and 71% of AML cases received chemotherapy. Among AUL patients who received chemotherapy, the median survival was 12 months as opposed to 1 month in the group who did not receive chemotherapy (or unknown status). Among adults, AUL patients had the worst prognosis, with a median overall survival (OS) of 9 months, compared to 27 months in ALL and 13 months in AML. Among children, the median OS was superior for all three groups of leukemias, the OS of AUL patients being better than in AML and very similar to ALL. On multivariate analysis, older age and time period were associated with worse outcome. We describe here the largest series of cases with AUL published to date.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Leuk Res Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Leuk Res Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido